GSK pays $1.2bn for liver drug as it culls TIGIT programme
GSK decided to abandon a TIGIT-targeted drug for cancer this week, then hatched a plan to replace it with a candidate for liver disease MASH.
Call goes out for feedback on US health deregulation
The Trump administration wants the public to join in the effort to cull redundant health regulations as part of its '10-for-one' deregulation policy.
UnitedHealth CEO Andrew Witty steps down
Andrew Witty has resigned as CEO of US health conglomerate UnitedHealth, as the company pulled its financial forecasts for 2025.
Q1 Clinical trials round-up: Jan-Mar 2025
The first quarter of 2025 saw a wave of significant advancements in clinical research across oncology, neurology, dermatology, respiratory, and rare diseases.
Featured Content
Latest News
Views & Analysis
Deep Dive
White Papers & Webinar
Podcasts & Video
Partner Content
Operationalize: Expanded Access Programs comes to the West C...
Improving Global Access to Life-Changing Therapeutics...
Injectable Drug Delivery 2025 – Driving Innovation Through C...
Press Release: Injectable Drug Delivery 2025 – Driving Innovation Through Collaboration LONDON, UK – 24–25 June 2025
4th In Vivo Cell Engineering & Gene Editing Summit
This forum brings together the brightest minds from biopharma, academia, and regulatory leadership to explore the full translational journey
6th Gene Therapy Analytical Development Summit Europe
Join 24+ expert speakers and over 90 industry stakeholders to unlock analytical strategies that elevate your development programmes,...
6th RNA Editing Summit | July 29-31, 2025 | Advance RNA Edit...
The 6th RNA Editing Summit returns to Boston this July, bringing together 60+ experts to propel the next generation of RNA editing therapies